TGFB1 and cancer: Inhibitors of TGFβ signaling have been evaluated in a number of clinical trials as a major pathway to improve the immune effect of cancer, and combining TGFβ related signals can enhance the effect of other immunosuppressants (Holmgaard et al., 2018; Tauriello et al., 2018).